Quigley To Commence Medical Feed Poultry Study For Its QR-441(a)

Quigley Pharma, a
wholly owned subsidiary of The Quigley Corporation (Nasdaq: QGLY),
announced today its forward motion for QR-441(a) as a first response agent
in safeguarding perimeter zones around a possible H5N1 outbreak in the
United States. A healthy chicken medical feed study is now being readied
for QR-441(a) under the direction of Dr. Timothy Cummings. In March of this
year, the Company announced that it would be initiating a series of
controlled experiments designed to test its all natural broad spectrum
antiviral compound QR-441 (a) against H5N1 (avian flu) in poultry stocks.


Delivering QR-441(a) via Poultry Medical Feed is to determine if this
form has advantages over other of modes of drug delivery. Medical Feed may
have several advantages such as safety and convenience as well as its
potential effect on fecal viral burden. Feces are the most important method
of viral transmission in poultry stocks.


Following this initial healthy chicken medical feed study the Company
plans to conduct challenge studies in chickens infected with H5N1. If the
initial studies show the medical feed option as unsuitable, the Company
will pursue other avenues of drug delivery.


"A compound such as QR-441(a) may provide the poultry industry and
government agencies an additional method to safeguard our nation's food
supply," stated Richard Rosenbloom, COO, Quigley Pharma.


Should an outbreak of H5N1 occur in the United States, the federal and
local government, working in conjunction with the poultry industry, will
likely establish a hot zone where all poultry will be slaughtered.
Immediately outside the hot zone will be a buffer zone perimeter in which
poultry will be at a greater risk of infection by H5N1 than those further
outside the hot zone. QR-441(a) is designed specifically for use in this
buffer zone perimeter.


QR-441(a) is made from botanical components and may be incorporated
into current poultry feed and water supplies, making the compound a
potential agent that might be used to reduce or eliminate the chance of
further infection immediately outside these H5N1 hot zones.


Other studies are now being designed to test if QR-441(a) will also
protect other animals, such as swine, within these H5N1 hot zones. Pigs are
a unique, important factor in fighting H5N1 as they are most likely to be
the breeding ground for mutations to H5N1 that might facilitate
transmission to and between humans.


QR-441(a) is a broad-spectrum antiviral compound that has been shown to
prevent the transmission of Influenza A in animal model studies and
demonstrated strong antiviral properties against the H5N1 virus in in-vitro
studies. Data has shown that this compound seems to prevent infectivity and
transmissibility of Influenza viruses.


The Quigley Corporation makes no representation that the U.S. Food and
Drug Administration or any other regulatory agency will allow the
aforementioned compound to be marketed as a veterinary drug. Furthermore,
no claim is made that the potential medicine discussed here is safe,
effective, or approved by the Food and Drug Administration.
The Quigley Corporation is the leading developer and marketer of
diversified health products. The company's proven success in launching
first- in-category health solutions supports the Pharma subsidiary in its
efforts to develop strong pharmaceutical compounds targeting diverse
conditions such as diabetes and rheumatoid arthritis with naturally derived
compounds and botanicals.















About The Quigley Corporation


The Quigley Corporation (Nasdaq: QGLY, Quigleyco) is a
diversified natural health medical science company. Its Cold Remedy segment
is a leading marketer and manufacturer of the COLD-EEZE(R) family of
lozenges, gums and sugar free tablets clinically proven to cut the common
cold nearly in half. COLD-EEZE customers include leading national
wholesalers and distributors, as well as independent and chain food, drug
and mass merchandise stores and pharmacies. The Quigley Corporation has
several wholly owned subsidiaries. Darius International markets health and
wellness products through its wholly owned subsidiary, InnerLight Inc.
Quigley Manufacturing Inc. consists of two FDA approved facilities to
manufacture COLD- EEZE(R) lozenges as well as fulfill other contract
manufacturing opportunities. Quigley Pharma Inc.
(QuigleyPharma) conducts research in order to develop and
commercialize a pipeline of patented botanical and naturally derived
prescription drugs.


Certain statements in this press release are "forward-looking
statements" within the meaning of the Private Securities Litigation Reform
Act of 1995 and involve known and unknown risk, uncertainties and other
factors that may cause the company's actual performance or achievements to
be materially different from the results, performance or achievements
expressed or implied by the forward-looking statement. Factors that impact
such forward-looking statements include, among others, changes in worldwide
general economic conditions, changes in interest rates, government
regulations, and worldwide competition.



The Quigley Corporation

quigleyco